Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses

被引:89
|
作者
Stassen, HH [1 ]
Angst, J [1 ]
DeliniStula, A [1 ]
机构
[1] F HOFFMANN LA ROCHE & CO LTD,CNS MED RES,CH-4002 BASEL,SWITZERLAND
关键词
D O I
10.1055/s-2007-979551
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The onset of action of antidepressant drugs was investigated on the basis of two independent, multicenter, double-blind studies, comparing amitriptyline (N = 120), oxaprotiline (N = 120), imipramine (N = 506) and moclobemide (N = 580) with placebo (N = 189 /+ 191). Highly significant differences between the active drugs and placebo were found with respect to the total number of improvers and the total number of responders. In addition, significant differences between treatment modalities showed up in both the percentage rate and the time distribution of premature withdrawals. However, among improvers, the distribution of time spans to onset of improvement was found to be independent of treatment modality, indicated by virtual ly identical cumulative percentages of improvers over the whole observation period. This picture of treatment-independent improvement rates was essentially the same for the HAMD, HAMA and ZUNG assessments, except for a significant time lag between observerratings and selfratings. Specifically, our analyses revealed no evidence for a delayed onset of action of various antidepressants with large biochemical and pharmacological differences when compared to placebo. The early onset of improvement was highly predictive of later outcome: on average, 70% of patients showing improvement within the first 14 days became responders. Differences between active treatments and placebo emerged within the first five days and reached a point of maximum distinction around day 14. After this time point, differences between treatment modalities remained constant until the end of the observation period. Not more than 20 - 25% of patients were, on average, ''true'' drug responders, thus suggesting that the therapeutic qualities of antidepressants do not lie in the suppression of symptoms, but rather relate to their ability to elicit and maintain certain conditions which enable recovery in a subgroup of patients who would otherwise remain nonresponders.
引用
收藏
页码:87 / 96
页数:10
相关论文
共 50 条
  • [21] Lag times in the publication of network meta-analyses: a survey
    Tonin, Fernanda S.
    Araujo, Ariane G.
    Fachi, Mariana M.
    Ferreira, Vinicius L.
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    BMJ OPEN, 2021, 11 (09):
  • [22] Survey of systematic reviews and meta-analyses published in ophthalmology
    Chen, Haoyu
    Jhanji, Vishal
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2012, 96 (06) : 896 - 899
  • [23] Psychological treatment of depression: Results of a series of meta-analyses
    Cuijpers, Pim
    Andersson, Gerhard
    Donker, Tara
    van Straten, Annemieke
    NORDIC JOURNAL OF PSYCHIATRY, 2011, 65 (06) : 354 - 364
  • [24] Does blinding of readers affect the results of meta-analyses?
    Berlin, JA
    LANCET, 1997, 350 (9072): : 185 - 186
  • [25] The heritability of human behavior: Results of aggregating meta-analyses
    Malouff, John M.
    Rooke, Sally E.
    Schutte, Nicola S.
    CURRENT PSYCHOLOGY, 2008, 27 (03) : 153 - 161
  • [26] Does blinding of readers affect results of meta-analyses?
    West, R
    LANCET, 1997, 350 (9081): : 892 - 892
  • [27] The Heritability of Human Behavior: Results of Aggregating Meta-Analyses
    John M. Malouff
    Sally E. Rooke
    Nicola S. Schutte
    Current Psychology, 2008, 27 : 153 - 161
  • [28] Efficacy of psychotherapy for patients with schizophrenia -: Results of meta-analyses
    Pitschel-Walz, Gabi
    Baeuml, Josef
    PSYCHIATRISCHE PRAXIS, 2007, 34 : S28 - S32
  • [29] Sclerotherapy versus vasoactive drugs: Are all meta-analyses the same?
    Triantos, C
    Samonakis, D
    Patch, D
    Burroughs, A
    Goulis, J
    GASTROENTEROLOGY, 2004, 127 (01) : 358 - 359
  • [30] Interpretation of network meta-analyses of the efficacy of rheumatoid arthritis drugs
    Urata, Yukitomo
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (06) : 1485 - 1488